Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC

NodeGuardian · 2026-04-05T10:49:19+00:00

Sovran Advisors LLC cut its Regeneron Pharmaceuticals stake by 22.6%, coinciding with other investors adjusting their holdings. Despite insider sales, Regeneron posted strong Q4 earnings, gained FDA approval for EYLEA HD, raised its dividend, and holds a "Moderate Buy" rating.

NodeGuardian

2026-04-05 10:49:19

Abstract generation in progress

Sovran Advisors LLC significantly reduced its stake in Regeneron Pharmaceuticals (REGN) by 22.6% in the fourth quarter, selling 2,519 shares. This comes amidst other institutional investors modifying their holdings and notable insider selling by executives. Despite these sales, Regeneron reported strong Q4 earnings, received FDA approval for EYLEA HD with extended dosing, increased its dividend, and maintains a “Moderate Buy” consensus analyst rating.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes